Table 1 Patient demographics and baseline characteristics
Phase 2 study (Group 1 and 2) (n = 7) | Immuno-PET study (n = 2) | ||
|---|---|---|---|
Sex, n (%) | |||
Male | 7 (100) | 1 (50) | |
Female | 0 (0) | 1 (50) | |
Mean (SD) age, years | 73.3 (4.07) | 77.5 (3.54) | |
Ethnicity | |||
Not Hispanic or Latino, n (%) | 7 (100) | 2 (100) | |
Race, n (%) | |||
White | 7 (100) | 2 (100) | |
Cardiac amyloidosis type, n (%) | |||
ATTR-CM | 6 (85.7) | 2 (100)a | |
AL | 1 (14.3) | 0 (0) | |
Mean (SD) cumulative miridesap dose, mg | Group 1 (n = 6) | 12,519.3 (3245.35) | 3394.0 (1406.61) |
Group 2 (n = 1) | 1291.0 | ||
Mean (SD) cumulative dezamizumab dose, mg | Group 1 (n = 6) | 5379.5 (1498.67) | 330.1 (353.1) |
Group 2 (n = 1) | 300.0 | ||